Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

TScan Therapeutics, Inc. Common Stock (TCRX)

Biological Products, (no Disgnostic Substances)

https://www.tscan.com

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

880 WINTER STREET
WALTHAM, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/16/2021

Market Cap

303,961,140

Shares Outstanding

43,550,000

Weighted SO

47,824,680

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

VECT --.--%

ICVX --.--%

APLS --.--%

ITOS --.--%

DAWN --.--%

ABOS --.--%

XFOR --.--%

INZY --.--%

CGTX --.--%

Beta

0.8230

Last Div

0.0000

Range

1.97-9.69

Chg

-0.0400

Avg Vol

367477

Mkt Cap

303961140

Exch

NASDAQ

Country

US

Phone

857 399 9500

DCF Diff

7.1394

DCF

0.0006

Div Yield

0.0000

P/S

24.9148

EV Multiple

-1.3858

P/FV

2.5554

Div Yield %

0.0000

P/E

-6.2463

PEG

-0.1322

Payout

0.0000

Current Ratio

7.7655

Quick Ratio

7.7655

Cash Ratio

6.2781

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

229.9737

CCC

-229.9737

Gross Margin

0.5954

Op Margin

-9.1469

Pretax Margin

-8.5584

Net Margin

-8.5584

Eff Tax Rate

0.0448

ROA

-0.2785

ROE

-0.5983

ROCE

-0.3318

NI/EBT

1.0000

EBT/EBIT

0.9357

EBIT/Rev

-9.1469

Debt Ratio

0.0909

D/E

0.1335

LT Debt/Cap

0.0730

Total Debt/Cap

0.1177

Int Coverage

54.6752

CF/Debt

-2.0915

Equity Multi

1.4688

Rec Turnover

0.0000

Pay Turnover

1.5871

Inv Turnover

0.0000

FA Turnover

0.1779

Asset Turnover

0.0325

OCF/Share

-0.6281

FCF/Share

-0.6585

Cash/Share

2.6244

OCF/Sales

-5.8394

FCF/OCF

1.0485

CF Coverage

-2.0915

ST Coverage

-5.1069

CapEx Coverage

-20.6197

Div&CapEx Cov

-20.6197

P/BV

2.5554

P/B

2.5554

P/S

24.9148

P/E

-6.2463

P/FCF

-4.0693

P/OCF

-9.1548

P/CF

-9.1548

PEG

-0.1322

P/S

24.9148

EV Multiple

-1.3858

P/FV

2.5554

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 09, 22:45 TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 12:00 TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 12:00 TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 12:00 TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 12:00 TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 12:00 TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition GlobeNewswire Inc. Dec 09, 12:00 TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Revenue Product Segmentation